MetLife Investment Management’s Anika Therapeutics ANIK Stock Holding History

MetLife Investment Management’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$103K	Buy	+7,122	New	+$82.7K	﹤0.01%	2528
2025 Q2	–	Sell	-8,516	Closed	-$128K	–	2789
2025 Q1	$128K	Hold	8,516	–	–	﹤0.01%	2412
2024 Q4	$140K	Hold	8,516	–	–	﹤0.01%	2473
2024 Q3	$210K	Hold	8,516	–	–	﹤0.01%	2263
2024 Q2	$216K	Buy	8,516 +831	+11%	+$21.5K	﹤0.01%	2195
2024 Q1	$195K	Hold	7,685	–	–	﹤0.01%	2222
2023 Q4	$174K	Hold	7,685	–	–	﹤0.01%	2314
2023 Q3	$143K	Hold	7,685	–	–	﹤0.01%	2391
2023 Q2	$200K	Hold	7,685	–	–	﹤0.01%	2279
2023 Q1	$221K	Hold	7,685	–	–	﹤0.01%	2153
2022 Q4	$227K	Sell	7,685 -845	-10%	-$24K	﹤0.01%	2170
2022 Q3	$203K	Hold	8,530	–	–	﹤0.01%	2291
2022 Q2	$190K	Hold	8,530	–	–	﹤0.01%	2354
2022 Q1	$214K	Buy	8,530 +3,582	+72%	+$109K	﹤0.01%	2319
2021 Q4	$177K	Sell	4,948 -2,139	-30%	-$85.6K	﹤0.01%	2125
2021 Q3	$302K	Hold	7,087	–	–	﹤0.01%	1819
2021 Q2	$307K	Hold	7,087	–	–	﹤0.01%	1871
2021 Q1	$289K	Hold	7,087	–	–	﹤0.01%	1832
2020 Q4	$321K	Hold	7,087	–	–	﹤0.01%	1725
2020 Q3	$251K	Hold	7,087	–	–	﹤0.01%	1722
2020 Q2	$267K	Hold	7,087	–	–	﹤0.01%	1727
2020 Q1	$205K	Hold	7,087	–	–	﹤0.01%	1683
2019 Q4	$367K	Hold	7,087	–	–	﹤0.01%	1626
2019 Q3	$389K	Hold	7,087	–	–	﹤0.01%	1558
2019 Q2	$288K	Hold	7,087	–	–	﹤0.01%	1813
2019 Q1	$214K	Hold	7,087	–	–	﹤0.01%	1946
2018 Q4	$238K	Hold	7,087	–	–	﹤0.01%	1809
2018 Q3	$299K	Hold	7,087	–	–	﹤0.01%	1859
2018 Q2	$227K	Hold	7,087	–	–	﹤0.01%	1870
2018 Q1	$352K	Hold	7,087	–	–	﹤0.01%	1591
2017 Q4	$382K	Buy	+7,087	New	+$392K	﹤0.01%	1564

Other funds holding ANIK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

MetLife Investment Management's ANIK Position: Q1 2026 in Review

MetLife Investment Management opened a new position in Anika Therapeutics (ANIK) in Q1 2026: 7,122 shares worth $103K. The stake represents ﹤0.01% of the portfolio and ranks #2528 among its holdings. This is a return to the name: MetLife Investment Management previously reported a position in ANIK as recently as Q1 2025.

MetLife Investment Management first reported a position in ANIK in Q4 2017 and has held it in 31 quarters since. The position peaked at $389K in Q3 2019. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

MetLife Investment Management held 7,122 shares of Anika Therapeutics worth $103K as of Q1 2026.
Anika Therapeutics was a new MetLife Investment Management position in Q1 2026.
Anika Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2528 holding.
MetLife Investment Management first reported a position in Anika Therapeutics in Q4 2017 and has held it in 31 quarters since.
MetLife Investment Management's Anika Therapeutics position peaked at $389K in Q3 2019.
130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.